ArticlePloS one2024
Modulatory action of Bryonia alba on the immune system in cyclophosphamide induced immunosuppression in BALB/c mice.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identifying immunostimulatory herbal supplements that may flare autoimmune skin diseases: a systematic scoping review.Lupus science & medicine · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress and inflammation are the most common pathologies in immune-compromised diseases and cancer treatments. The study examined the immune stimulation properties of Bryonia alba (BA) in different potencies (6C, 30C, and 200C) on a BALB/c mice model with a compromised immune system induced by cyclophosphamide (CPM) at a dose of 80 mg/kg. Seventy mice (35 males and 35 females) were randomly distributed into seven groups of 5 animals/sex. Mice treated with different potencies of BA showed notable improvements in various immune parameters, including RBC, WBC, and Hb levels, as well as thymus and phagocytic indices. Treatment also increased serum levels and splenic mRNA expression of IL-2, IL-4, TNF-α, and IFN-γ. The histopathology analysis showed that the spleen sections of the normal group exhibited intact white and red pulp. In contrast, the sections of the CPM group exhibited disrupted and atrophied white pulp. The treatment with BA maintained the spleen in a preserved state, with the white and red pulp remaining intact and a higher density of lymphocytes. The results indicate that BA could serve as a valued immunostimulant agent when administered with chemo-therapy. However, additional research is required to assess the immunostimulatory effects of BA in immune-compromised infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.